Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLDN6 antibody-drug conjugate DS-9606a

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 6 (CLDN6; CLDN-6) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-CLDN6 ADC DS-9606a, the anti-CLDN6 antibody moiety targets and binds to CLDN6-expressing tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the CLDN6-expressing tumor cells, through an as of yet unknown mechanism of action. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CLDN6 ADC DS-9606
anti-CLDN6 ADC DS-9606a
Code name:DS 9606
DS 9606a
DS-9606
DS-9606a
DS9606
DS9606a
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search